Stockscreener 앱 받기
45.95
1.30%
0.59
시장 영업 전:
46.10
0.15
+0.33%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Yan Leyfman: FDA Accepts Bristol Myers Squibb's Breyanzi for Priority Review as a Potential Treatment for Relapsed MZL - Oncodaily
Jim Cramer on Bristol-Myers: “Have Not Been Recommending the Stock” - Insider Monkey
Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector? - MSN
Bristol Myers Squibb Named Top Dividend Stock With Insider Buying and 5.47% Yield (BMY) - Nasdaq
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
Car T Cell Therapy For Multiple Myeloma Market Growth to Accelerate in Forecast Period (2024-2032), DelveInsight Analyzes by DelveInsight | Johnson & Johnson, Gadeta, Bristol-Myers Squibb, Bluebird - Barchart.com
Stock Analysis | Bristol-Myers Squibb OutlookNavigating Weak Technicals Amid Mixed Fundamentals - AInvest
FDA Accepts Breyanzi sBLA from Bristol Myers Squibb and Grants It Priority Review for MZL - BioPharm International
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised - Investing.com Nigeria
Bristol Myers Squibb Q1 2025 slides: portfolio transformation gains momentum as guidance raised By Investing.com - Investing.com South Africa
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
3 Dividend Stocks for August 2025 - Morningstar
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - MSN
Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity (NYSE:BMY) - Seeking Alpha
BioNTech Outlines Development Plan For PD-L1xVEGF-Targeting BNT-327 - insights.citeline.com
Morgan Stanley Maintains a Sell Rating on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - Yahoo Finance
BioNTech shares rise over 2% as Q2 revenue doubles, Bristol Myers deal bolsters outlook - Investing.com
Bristol-Myers Squibb: Is the 30% Pullback a Strategic Buy Opportunity? - AInvest
Bristol-Myers Squibb (BMY) Stock Analysis: Exploring a 22.84% Upside Potential with a Robust Dividend Yield - DirectorsTalk Interviews
Bristol-Myers Squibb (BMY) Is Down 8.7% After Lowering Guidance Amid Strategic Shift and Generic Pressure - simplywall.st
BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 To Go Ex-Dividend On August 5th, 2025 With 0.5 USD Dividend Per Share - 富途牛牛
What makes Bristol Myers Squibb Company Equity Right stock price move sharplyExceptional earning trajectories - Jammu Links News
Bristol-Myers Squibb: Declines Have Gone Too Far (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu - Insider Monkey
Bristol-Myers Squibb Reports Strong Q2 2025 Results - The Globe and Mail
Bristol-Myers Squibb: No Respect For Blowout EarningsBuy The Richer Dividend Yields - Seeking Alpha
Bristol Myers Squibb presents new PROTACs for autoimmune and inflammatory disorders - BioWorld MedTech
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript - Insider Monkey
Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges - TipRanks
Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz - pehub.com
11 Best Medical Stocks to Buy According to Analysts - Insider Monkey
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: Robust Growth and Strategic ... By GuruFocus - Investing.com Canada
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: - GuruFocus
What are the technical indicators suggesting about Bristol Myers Squibb Company Equity RightAI Powered Review For 2025 - jammulinksnews.com
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025 - Insider Monkey
Bristol-Myers Squibb Earnings: A Strong Second Quarter, but Upcoming Data Readouts in Focus - Morningstar
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol Myers tops revenue expectations on strength of older drugs, shares fall By Reuters - Investing.com
Earnings call transcript: Bristol-Myers Squibb Q2 2025 sees earnings beat but stock dips - Investing.com Canada
Bristol Myers tops revenue expectations on strength of older drugs, shares fall - MarketScreener
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
Bristol Myers posts better-than-expected second quarter results on strength of top sellers - Bilyonaryo Business News
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic - Yahoo Finance
Bristol Myers raises guidance as Q2 results beat forecasts - The Pharma Letter
Bristol Myers Squibb Q2 2025 Earnings Call Transcript - MarketBeat
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion - Yahoo Finance
Is Wall Street Bullish or Bearish on Bristol-Myers Stock? - Yahoo Finance
Bristol-Myers Squibb stock hits 52-week low at 43.89 USD - Investing.com Nigeria
Bristol-Myers Squibb Co reports results for the quarter ended June 30Earnings Summary - TradingView
Bristol Myers Squibb's 2025 EPS Target Revisions: A Strategic Realignment for Long-Term Growth - AInvest
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations - The Wall Street Journal
Bristol-Myers Squibb Co Surpasses Revenue Estimates with $12.3 Billion, Non-GAAP EPS of $1.46 Exceeds Expectations - GuruFocus
Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio - Investing.com Nigeria
0.63%
1.44%
자본화:
|
볼륨(24시간):